Literature DB >> 3731061

Heparan sulfate endoglycosidase and metastatic potential in murine fibrosarcoma and melanoma.

W Ricoveri, R Cappelletti.   

Abstract

Several fibroblast and melanoma cell lines were studied with respect to their ability to degrade heparan sulfate (HS). The optimum pH for HS degradation by HS endoglycosidase (heparanase) for all cell lines is about 5.6, but the activity of the enzyme is still present at physiological pH. The gel permeation analysis of degradation products revealed that heparanase cuts HS in fragments about one-seventh of their original size. Since the optimum pH of HS endoglycosidase activity and the terminal molecular weight of degraded HS are the same in both cell lines, it is likely that fibrosarcoma and melanoma heparanases are identical enzymes. Cell extracts and intact cells of metastatic sublines degrade HS faster than do their nonmetastatic counterparts. The degradative activity of intact cells parallels those of cell extracts, but at a much lower level; moreover, conditioned media do not appreciably degrade HS, suggesting that heparanase is scarcely released into the medium; thus, considering the differences in degradative activity between cell extracts and intact cells or conditioned medium and the occurrence of cell lysis in a tumor in vivo, we suggest that the measure of degradative activity of intact cells in vitro is not indicative of a relationship to metastasis. The total cellular content of lytic enzymes could represent the real metastatic potential of proliferating cells, but it is also necessary to find an in vitro model better representing the behavior of neoplastic cells in vivo.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3731061

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  12 in total

1.  A rapid quantitative assay for the detection of mammalian heparanase activity.

Authors:  C Freeman; C R Parish
Journal:  Biochem J       Date:  1997-07-01       Impact factor: 3.857

Review 2.  Cell-matrix interactions during tumor invasion.

Authors:  J R Starkey
Journal:  Cancer Metastasis Rev       Date:  1990-09       Impact factor: 9.264

3.  Clinicopathological significance of heparanase and basic fibroblast growth factor expression in human esophageal cancer.

Authors:  Biao Han; Jian Liu; Min-Jie Ma; Lin Zhao
Journal:  World J Gastroenterol       Date:  2005-04-14       Impact factor: 5.742

4.  Evidence that platelet and tumour heparanases are similar enzymes.

Authors:  C Freeman; A M Browne; C R Parish
Journal:  Biochem J       Date:  1999-09-01       Impact factor: 3.857

5.  Human platelet heparanase: purification, characterization and catalytic activity.

Authors:  C Freeman; C R Parish
Journal:  Biochem J       Date:  1998-03-15       Impact factor: 3.857

6.  Accumulation of heparan sulfate in the culture of human melanoma cells with different metastatic ability.

Authors:  M Moczar; F Caux; M Bailly; O Berthier; J F Doré
Journal:  Clin Exp Metastasis       Date:  1993-11       Impact factor: 5.150

7.  Tumour rejection antigens of the hsp90 family (gp96) closely resemble tumour-associated heparanase enzymes.

Authors:  L D Graham
Journal:  Biochem J       Date:  1994-08-01       Impact factor: 3.857

8.  Structural differences between heparan sulphates of proteoglycan involved in the formation of basement membranes in vivo by Lewis-lung-carcinoma-derived cloned cells with different metastatic potentials.

Authors:  H Nakanishi; K Oguri; K Yoshida; N Itano; K Takenaga; T Kazama; A Yoshida; M Okayama
Journal:  Biochem J       Date:  1992-11-15       Impact factor: 3.857

9.  Syndecan-1 alterations during the tumorigenic progression of human colonic Caco-2 cells induced by human Ha-ras or polyoma middle T oncogenes.

Authors:  P Levy; A Munier; S Baron-Delage; Y Di Gioia; C Gespach; J Capeau; G Cherqui
Journal:  Br J Cancer       Date:  1996-08       Impact factor: 7.640

10.  Molecular behavior adapts to context: heparanase functions as an extracellular matrix-degrading enzyme or as a T cell adhesion molecule, depending on the local pH.

Authors:  D Gilat; R Hershkoviz; I Goldkorn; L Cahalon; G Korner; I Vlodavsky; O Lider
Journal:  J Exp Med       Date:  1995-05-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.